Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, December 19, 2017
Mon, December 18, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, December 15, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jami Rubin Upgraded (TEVA) to Strong Buy on, Dec 15th, 2017
Jami Rubin of Goldman Sachs, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Strong Buy on, Dec 15th, 2017.
Jami has made no other calls on TEVA in the last 4 months.
There are 6 other peers that have a rating on TEVA. Out of the 6 peers that are also analyzing TEVA, 4 agree with Jami's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Rohit Vanjani of "Guggenheim" Initiated at Hold and Held Target at $16 on, Tuesday, December 12th, 2017
- Liav Abraham of "Citigroup" Maintained at Hold with Decreased Target to $13 on, Monday, November 13th, 2017
- Gregg Gilbert of "Deutsche Bank" Downgraded from Strong Buy to Hold on, Friday, November 3rd, 2017
- Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017
These are the ratings of the 2 analyists that currently disagree with Jami
- Chris Schott of "JP Morgan" Downgraded from Hold to Sell on, Monday, November 13th, 2017
- Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
